Axa
LVTX

Axa’s LAVA Therapeutics LVTX Stock Holding History

Axa’s Portfolio LVTX Stock Details LVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-225,748
Closed -$375K – 1130
2023
Q1 		$375K Sell
225,748
-1,733
-0.8% -$4.85K ﹤0.01% 997
2022
Q4 		$796K Sell
227,481
-1,190
-0.5% -$5.46K ﹤0.01% 923
2022
Q3 		$1.05M Buy
228,671
+1,198
+0.5% +$3.3K ﹤0.01% 853
2022
Q2 		$671K Sell
227,473
-4,413
-2% -$15.3K ﹤0.01% 933
2022
Q1 		$1.02M Buy
231,886
+2
+0% +$10 ﹤0.01% 950
2021
Q4 		$1.27M Buy
231,884
+2,763
+1% +$18.1K ﹤0.01% 918
2021
Q3 		$1.36M Buy
229,121
+8,458
+4% +$60.9K ﹤0.01% 934
2021
Q2 		$2.4M Buy
220,663
+300
+0.1% +$3.72K 0.01% 856
2021
Q1 		$3.35M Buy
+220,363
New +$3.03M 0.01% 769

Other funds holding LVTX

NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BC
Bruce & Co Chicago, Illinois $369M AUM 50.95% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
AWG
Alpha Wave Global New York $6.24B AUM 59.73% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $202B AUM 37.79% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

Axa's LVTX Position: Q2 2023 in Review

Axa sold out of LAVA Therapeutics (LVTX) in Q2 2023, closing a stake of 225,748 shares — an estimated $375K sold.

Axa first reported a position in LVTX in Q1 2021 and held it in 9 quarters. The position peaked at $3.35M in Q1 2021. 15 funds tracked by Wall St. Rank hold LVTX as of Q2 2023.

  • Axa reported no remaining LAVA Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Axa sold 225,748 LAVA Therapeutics shares in Q2 2023, an estimated $375K.
  • Axa first reported a position in LAVA Therapeutics in Q1 2021 and held it in 9 quarters.
  • Axa's LAVA Therapeutics position peaked at $3.35M in Q1 2021.
  • 15 funds tracked by Wall St. Rank held LAVA Therapeutics as of Q2 2023.

Based on Axa's 13F filing for Q2 2023, filed 14 Aug 2023.